CIRCA TO RECEIVE 20% OF RPR DILACOR XR SALES IN 1995
Executive Summary
CIRCA TO RECEIVE 20% OF RPR DILACOR XR SALES IN 1995, Circa Chairman Melvin Sharoky told analysts at the Bear Stearns Seventh Annual Health Care meeting in New York City Sept. 21. Circa, formerly Bolar, receives a 1% royalty on sales of the once-daily diltiazem product under an agreement with Rhone-Poulenc Rorer dating back to 1989, Sharoky said.